HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma by Moelans, Cathy B. et al.
SAGE-Hindawi Access to Research
Pathology Research International
Volume 2011, Article ID 674182, 10 pages
doi:10.4061/2011/674182
Review Article
HER-2/neu Testing and Therapy in Gastroesophageal
Adenocarcinoma
CathyB. Moelans,PaulJ. vanDiest,AnyaN. A.Milne,and G.Johan A.Offerhaus
Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, P.O. Box 85500,
3508 GA Utrecht, The Netherlands
Correspondence should be addressed to Cathy B. Moelans, cmoelans@umcutrecht.nl
Received 19 August 2010; Accepted 25 October 2010
Academic Editor: Rhonda K. Yantiss
Copyright © 2011 Cathy B. Moelans et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Despite ongoing advances in the treatment of gastroesophageal cancer, prognosis remains poor. The best promise to improve
this poor survival is provided by new targeted agents. Of these, human epidermal growth factor receptor 2 (HER2) is currently
in the spotlight. In this review, we provide an overview of recent developments in HER2 testing and results of clinical trials
targetingHER2ingastroesophagealadenocarcinoma.BasedontheencouragingToGAtrialﬁndingsitisnowexpectedthatroutine
HER2 testing will be included in the diagnostic work-up of patients with advanced gastric cancer. With regard to this testing,
overexpressionoftheHER2proteinseemstopossessthebestpredictiveproperties.However,HER2immunohistochemistry(IHC)
is subject to assay and interobserver variability, so standardization and internal and external proﬁciency testing is an absolute
prerequisite, especially as the IHC scoring system in gastric cancer is diﬀerent from that of breast cancer. Further study is needed
to investigate the clinical meaning of the signiﬁcant heterogeneity observed in both gene ampliﬁcation and protein overexpression
in gastroesophageal cancer. Highly eﬀective therapies for gastroesophageal cancer can only be accomplished by a multi-targeted
approach, considering crosstalk between pathways and continuing to optimize chemotherapy.
1.Introduction
Despite ongoing advances in the treatment of gastroe-
sophageal cancer, prognosis remains poor. Esophageal ade-
nocarcinoma incidence has been rapidly increasing in West-
ern countries during the past half century, especially in
Caucasian males. This is believed to be attributable to the
increased prevalence of gastroesophageal reﬂux disease and
its major determinant, obesity [1], resulting in Barrett’s
esophagus. Esophageal adenocarcinoma arising in Barrett’s
esophagushasapoorprognosiswitha5-yearrelativesurvival
of 10–20%. Gastric cancer aﬀects about one million people
per year and is the second leading cause of cancer-related
mortality worldwide [2]. Gastric cancer is thought to result
from a combination of environmental factors and accu-
mulation of speciﬁc genetic alterations, and consequently,
mainly aﬀects older patients. Gastric cancer exists as two
main histological types, diﬀuse and intestinal, as described
by Lauren [3], and can be subdivided into proximal (cardia)
and distal (corpus and pylorus) cancers. Interestingly, there
seems to be a trend towards more proximally (cardiac)
located gastric cancer. This distal to proximal shift is yet
incompletely understood and seems to parallel the observed
recent rise in incidence of Barrett’s esophagus. This fall in
incidence in mid- and distal gastric cancer may be explained
by the decline in Helicobacter pylori infection and associated
atrophic gastritis. When a tumor is located at the gastroe-
sophageal junction, it is often unknown whether the tumor
is of esophageal or gastric origin. This group of cancers is
therefore called “gastroesophageal junction cancers.” Surgery
is the mainstay of treatment for resectable adenocarcinomas
ofstomachandesophagus,butrecurrenceratesarehigheven
after radical resection. In Western countries, most patients
are diagnosed at an advanced (unresectable) stage and,
despitebeneﬁtsofpalliativeradiotherapyandchemotherapy,
survival of patients with advanced tumors remains poor
(median survival 7–10 months) [4]. The best promise to
improve this poor survival is provided by new agents2 Pathology Research International
acting against speciﬁc molecular targets. Of these, HER2
is currently in the spotlight. The aim of this paper is to
provide an overview of recent developments in HER2 testing
and results of clinical trials targeting HER2 in gastric and
esophageal adenocarcinoma. Since most studies combine
Barrett’s esophagus, gastroesophageal junction cancers, and
gastric cancer, the term “gastroesophageal” is used to refer to
this combined group.
2. Human Epidermal GrowthFactor Receptor 2
HER-2/neu (HER2) is a proto-oncogene located on chromo-
some 17q21 and a member of the human epidermal growth
factor receptor (EGFR) family. It encodes a 185kD trans-
membrane tyrosine kinase receptor protein that, through
dimerisation with other family members, regulates signal
transduction in cellular processes including proliferation,
diﬀerentiation, and cellular survival [5, 6]. Many studies
have indicated a role of HER2 in the development of
various types of human cancer. HER2 is ampliﬁed, and
the expression of its receptor protein is increased in about
10–20% of breast carcinomas [7–11]. HER2 ampliﬁcation
and/or overexpression have also been observed in colon [12],
bladder [13], ovarian [14], Fallopian tube [15], endometrial
[16], lung [17], uterine cervix [18], head and neck [19],
prostate [20], pancreatic [21], salivary gland [22], and
esophageal [23]a n dg a s t r i c[ 24] carcinomas.
Patients with HER2-positive (ampliﬁcation and/or over-
expression) primary and metastatic breast tumors have
increasedsurvivalrateswhentreatedwithtrastuzumab(Her-
ceptin), a recombinant humanized monoclonal anti-HER2
antibody [25, 26]. The eﬃcacy of trastuzumab in breast
cancerpatientsurgedinvestigationintoitsantitumoractivity
in patients with other HER2-positive cancers, including gas-
troesophageal cancer. Furthermore, overexpression [27]a n d
ampliﬁcationofHER2[28]havealsobeenshowntocorrelate
with poor prognosis and with resistance to conventional
adjuvant chemotherapy and tamoxifen [29–33]i nb r e a s t
cancer.Withtherecognitionofitsprognostic,predictive,and
therapeuticimplications,assessmentofHER2statushasnow
become of major importance in clinical practice for cancer
patients.
2.1. Diagnostic Tests to Detect HER2 Ampliﬁcation and Over-
expression. Since the costs for trastuzumab therapy are high
and side eﬀects are signiﬁcant, accurate selection of eligible
patients for this therapy is crucial. Since 1998, trastuzumab
has been used to treat more than 740,000 patients with
HER2-positive breast cancer worldwide, so there is much
to learn from the diagnostic methods used in the selection
of breast cancer patients for this treatment. HER2 status
is mainly assessed by immunohistochemistry (IHC) and
chromogenic (CISH) or ﬂuorescence in situ hybridization
(FISH).
At present, the most common method to assess HER2
status is IHC [11] which is a routine technique available
in most pathology laboratories to detect protein expression
levels. Among HER2 IHC scoring systems for breast cancer,
the HercepTest (Dako, Glostrup, Denmark) is frequently
used to evaluate patterns of membranous immunoreactivity
on tumor cells. The scoring system is based on intensity
of reactivity, whether complete or incomplete and the
percentage of reactive cells. Patterns are scored as IHC 0 (no
staining or staining in <10% of tumor cells, negative), IHC
1+ (faint/barely perceptible incomplete membrane staining
in>10%oftumorcells,negative),IHC2+(weaktomoderate
complete membrane staining in >10% of tumor cells,
equivocal), or IHC 3+ (strong complete membrane staining
in >10% (until 2007) or >30% (2007–now) of tumor cells,
positive) [34]. Although staining and scoring methodology
has been better standardized with the introduction of the
Hercep Test than for most IHC assays, IHC is aﬀected
by poor tissue ﬁxation, and there are still problems with
reproducibility and interpretation of IHC assays [35–37],
leading to both false negative and false positive IHC results.
In addition, in breast cancer, there is some evidence that
testing for HER2 gene ampliﬁcation provides better pre-
dictive information than IHC [38–41]. Gene ampliﬁcation
testing was traditionally mostly done by FISH. For FISH
assessments, an HER2:CEP17 (centromeric probe 17) ratio
of >2.2 is now used (≥2.0 before 2007) to deﬁne HER2
positivity (ampliﬁcation), and ratios of 1.8–2.2 and <1.8 are
used to deﬁne equivocal and negative categories, respectively
[34].
Comparative studies of FISH and IHC have generally
shown a high level of concordance in breast cancer [39, 42,
43]. Discordant results were mainly observed for tumors
that were scored 2+ by IHC. However, pathologists have
been reluctant to embrace routine FISH testing, because it
is a diﬃcult, expensive, and cumbersome technique that
requires trained personnel which is not available in every
pathology laboratory. Moreover, ﬂuorescence fades upon
storage, making it diﬃcult to preserve the slides for future
reference,andtheﬂuorescentprobesinthekitshavealimited
half life. Furthermore, detailed morphological features of
the tumor are usually diﬃcult to observe due to the
required protein digestion and the ﬂuorescent mode, and
heterogeneitycanbemissedsincespotsareevaluatedat ×100
magniﬁcation using oil immersion.
Chromogenic in situ hybridization (CISH) was intro-
duced as an alternative for FISH in 2000 by Tanner et al.
[44], using an immunoperoxidase reaction to detect speciﬁc
DNA probes, which makes visualization possible with a
conventional bright ﬁeld microscope. Furthermore, similar
to IHC, a permanent staining record is retained, and better
morphologic examination is possible facilitating detection of
heterogeneity. This is important in gastroesophageal cancer
since higher rates of heterogeneity have been reported in
gastric cancer (5%) compared to breast cancer (1.5%) [45].
CISH is also easier to interpret for pathologists who are not
trained in ﬂuorescence microscopy, and it is less expensive
thanFISH.InCISHscoring,thepresenceoflargeperoxidase-
positive intranuclear clusters or >10 individual small signals
in >50% of tumor cells (counted in at least 20 tumor cells)
indicates HER2-positivity (ampliﬁcation). The presence
of small peroxidase-positive intranuclear clusters or 6–10
individual small signals indicates a low-level ampliﬁcation,Pathology Research International 3
and 5 or less individual small signals are scored as HER2-
negative [34].
In several breast cancer studies, HER2 CISH correlated
well with FISH and IHC [44, 46–51]. In gastric cancer, one
studysystematicallyanalyzedtheconcordancebetweenCISH
and FISH assays and observed a perfect correlation in 128
samples [52]. However, one drawback of CISH assays is that
ampliﬁcation can only be assessed semiquantitatively. There-
fore, detection of ampliﬁcation by easier quantitative PCR
techniques has been proposed as an alternative. One of the
newly introduced techniques for detection of HER2 ampli-
ﬁcation in breast cancer is multiplex ligation-dependent
probeampliﬁcation(MLPA)[53].Thistechniquedetermines
relativecopynumbersinaquantitativewayandrequiresonly
minute quantities of small DNA fragments, which makes
it very suitable for DNA isolated from paraﬃn-embedded
material.Inpreviousstudiesinbreastcancer,excellentresults
were obtained with MLPA in comparison with IHC, CISH
and FISH [10, 11, 51, 54, 55]. All currently available Food
and Drug Administration approved or Clinical Laboratory
Improvement Amendment validated HER2 tests have been
recently summarized by Allison [56].
To eliminate discrepancies observed between IHC and
FISH,H ofmannetal.[45]establishedanIHCscoringsystem
speciﬁc for gastric cancer. In an international consensus
meeting, modiﬁcations to the breast scoring system were
mademainlybasedonthemorefrequentbasolateral(incom-
plete) membrane staining and heterogeneity in gastric
cancer. This new scoring system, illustrated in Table 1,h a s
also been used to select patients for a clinical trial to evaluate
trastuzumab eﬃcacy and safety in HER2-positive advanced
esophageal and gastric cancer [57]. A subsequent study
validated these guidelines in terms of interlaboratory and
interobserver consensus in a large series of gastric cancer
and formulated additional speciﬁc recommendations [58].
Forexample,forreproducibleintensityscoring,thedegreeof
microscopic magniﬁcation (×-fold) at which membranous
(linear intercellular) staining is clearly visible should be
considered. Strong tumor HER2 IHC staining is usually
alreadydirectlyvisible.Inthesecases,onlylowmagniﬁcation
(×2.5–5) is needed to conﬁrm strong staining intensity.
In any case where high magniﬁcation (×40) is required
for unequivocal demonstration of membranous staining,
the tumor is scored IHC 1+. The interobserver variation
results within a ring-study prior and after application of
the magniﬁcation rule clearly were in favor of such an
approach over nonstandardized wording, for example, of
“barely visible” for IHC 1+.
2.2. Relationship between HER2 Ampliﬁcation and HER2
Overexpression. Ninestudies(totalling1,232samples)exam-
ining the frequency of HER2 ampliﬁcation in gastroe-
sophageal cancer showed a mean HER2 positivity rate of
19.2% (range 7–43%) [45], which is similar to the reported
percentage of protein overexpression.
In breast cancer, it is generally thought that HER2
overexpression is the direct result of gene ampliﬁcation [59].
In esophageal and gastric cancer, concordance percentages
Table 1: Consensus panel recommendations on HER2 scoring for
gastric cancer [45, 58].
Reactivity characteristics Score/classiﬁcation
No reactivity or membranous reactivity in
<10% of tumor cells 0/negative
Faint/ barely perceptible membranous
reactivity in >10% of tumor cells; cells are
reactive only in part of their membrane, in
any case where high magniﬁcation (×40) is
required for unequivocal demonstration of
membranous staining
1+/negative
Weak to moderate complete or basolateral
membranous reactivity in >10% of tumor
cells
2+/equivocal
Moderate to strong complete or basolateral
membranous reactivity in >10% of tumor
cells; only low magniﬁcation (×2.5–5) is
needed to conﬁrm strong staining
intensity.
3+/positive
Biopsy (not surgery) samples with cohesive
either IHC3+ and/or FISH+ clones (at
least 5 cells) are considered positive
irrespective of size, that is <10% of tumor
area
3+/positive
FISH: ﬂuorescence in situ hybridization; HER2: human epidermal growth
factor receptor 2; IHC: immunohistochemistry.
between ampliﬁcation and overexpression reported in litera-
ture range between 86.9 and 96.4% [60], as illustrated in Fig-
ure 1. Nevertheless, primary results from a very recent phase
III trial (ToGA) containing >3,800 advanced esophageal
and gastric cancer samples showed that the frequency
of samples with ampliﬁcation but without corresponding
overexpression was high (23%) compared to that in breast
cancer suggesting that FISH testing may be the more relevant
procedure to conduct on these tumor specimens [61].
However, preliminary data from this same trial reported
that patients with ampliﬁed tumors without overexpression
(IHC 0 or 1+) did not show a substantial overall survival
beneﬁt from trastuzumab (HR 1.07, median overall survival
10.0 months versus 8.7 months) in contrast to patients with
IHC 2+/FISH positive or IHC 3+ tumors (HR 0.65, median
overall survival 16.0 months versus 11.8 months) [57], sug-
gesting that measuring HER2 at the protein level should be
the primary screening method for selecting gastroesophageal
cancer patients for trastuzumab therapy. Final publication
of these trial data needs to be awaited to draw ﬁrmer
conclusions, and further research may be necessary to clarify
these ﬁndings. The pattern seen in breast cancer, where
ampliﬁcation of HER2 leads to an overexpression of the
protein,doesnotseemtohavebeenfullyconﬁrmedingastric
cancer yet. If the observations in the ToGA trial are correct,
this might be similar to what has been reported with another
gene/protein relationship in breast cancer: topoisomerase II
alpha (TOP2A). Unlike TOP2A, HER2 protein expression is
not cell-cycle dependent, so other mechanisms (increased
receptor degradation, transcriptional repression) may lay
behind this discrepancy. Also, gastric cancer may have more4 Pathology Research International
inherent genomic instability than breast cancer resulting in
more genes which are ampliﬁed as a bystander eﬀect and
not necessarily resulting in a functional increase of protein
expression.
2.3. HER2 Expression in Gastroesophageal Cancer. Reported
rates of HER2 overexpression in gastroesophageal cancer
vary widely (2–45%) due to small sample sizes, diﬀerences
in patient populations and methodological and scoring
diﬀerences between studies [45, 62–67]. In addition, dif-
ferences between HER2 overexpression in European and
Asian/South-American populations (22–28% versus 3–15%,
resp.) have been reported by some studies [68], but others
have found these diﬀerences to be less substantial [69].
The largest data set of >3,800 advanced esophageal and
gastric cancer samples found HER2 protein positivity rates
of 23% [57, 68]. A recent review combining data from
24 studies (6,542 patients) calculated a weighted mean of
19% HER2 positivity [60]. In the few studies that reported
separate HER2 positivity rates for gastroesophageal junction
cancers and gastric cancer, HER2 positivity was higher in
gastroesophageal junction cancer (24–35%) than in gastric
cancer (9.5–21%) [65, 68, 70, 71].
2.4. HER2 in Esophageal Cancer. The data on HER2 over-
expression in esophageal cancer are variable, with most
studies showing HER2 overexpression in 9%–60% of cases,
whereas other reports failed to observe HER2 expression
[72]. The diﬀerences among reported overexpression rates
might depend on stage of the disease, tumor histology
(adenocarcinomaversussquamouscellcarcinoma),method-
ology, and interpretation of IHC results. The relationship
between HER2 expression and the prognosis of patients with
esophageal cancer is not clear. It has been demonstrated that
HER2 overexpression correlates with tumor invasion and
lymph node metastasis, and thus indicates a poor prognosis
[71, 73–75].
Studies that speciﬁcally analyzed HER2 expression
and/or ampliﬁcation in Barrett’s esophagus reported pos-
itivity rates of 38–50% and showed an association with
progression from Barrett’s esophagus to dysplasia and ade-
nocarcinoma [76–79]. A very small pilot study showed
that trastuzumab treatment caused HER2 downregulation
and increased apoptosis in patients with dysplasia and
adenocarcinoma arising in Barrett’s esophagus [80].
2.5. HER2 in Gastric Cancer. Previous studies have shown
that early-onset gastric cancer (presenting at the age of 45
y e a r so ry o u n g e r )f o r m sas m a l l( <10%) [81] but distinct
group of gastric cancers with a diﬀerent molecular expres-
sion proﬁle than conventional gastric cancer [82–84]. We
recently showed that these younger patients show very low
(<5%) HER2 ampliﬁcation and overexpression frequencies
(unpublished data). Common gastric tumors classiﬁed as
intestinal typearemorelikelytobeHER2-positive (16–34%)
than diﬀuse (2–7%) or mixed (5–20%) types [65, 68, 70].
The reason for the selective overexpression of HER2 in
intestinal-type gastric cancers is complex and needs further
investigation. The association of HER2 with a speciﬁc type
suggests that intestinal- and diﬀuse-type gastric cancers
develop along diﬀerent molecular pathways and supports
earlierstudiesshowingdistinctpatternsofgeneticalterations
in gastric cancers of diﬀering histopathologic features [85].
Some similarities can be drawn with breast cancer: diﬀuse-
type gastric cancers and lobular invasive breast carcinomas
are both associated with E-cadherin loss, which is inversely
correlated with HER2 ampliﬁcation/overexpression which
is more common in ductal invasive breast carcinomas and
intestinal-type gastric cancers.
Although some studies have reported that HER2 ampli-
ﬁcation and overexpression are highly homogeneous within
a tumor and between primary and metastatic gastric cancer
[62], others have reported signiﬁcant heterogeneity in both
gene ampliﬁcation and protein overexpression in individual
cancers, even among IHC 3+ cancers [67, 86]. Some studies,
including our own ﬁndings (unpublished data), showed
homogeneous HER2 gene ampliﬁcation but heterogeneous
HER2 protein expression in certain samples, indicating that
false negatives might arise when IHC is employed to predict
trastuzumab response, especially when insuﬃcient material
is examined, such as in gastric biopsy specimens [52].
Generally, higher rates of HER2 heterogeneity have been
reported in gastric cancer (5%) compared to breast cancer
(1.5%) [45]. Chromosomal instability is probably one of the
major causes of this heterogeneity. It needs to be shown
whether patients with small cohesive HER2-positive clones
show a diﬀerent response to trastuzumab compared with
patients with extended HER2-positive areas.
Although reports are conﬂicting, some studies have
suggested that HER2-positive status in gastric cancer is asso-
ciated with poor outcomes and aggressive disease [65, 70].
3.PreclinicalandClinicalData:
Anti-HER2 Therapy
Several studies have indicated antitumor activity of trastuz-
umab and lapatinib in human gastric cancer cell lines (NCI-
N87, 4-1ST, SMU-216, MKN-45P) or xenograft models
which overexpress HER2 [65, 87–90]. In these preclinical
studies, these targeted compounds have been shown to
be eﬀective both as single agents and in combination
with chemotherapeutic agents that are widely used for the
treatment of gastric cancer. The three-drug combination of
capecitabine (Xeloda, Roche), cisplatin, and trastuzumab
showed a remarkable tumor inhibitory eﬀect in the NCI-
N87 tumor xenograft model, and it is this drug combination
that was also used in the ToGA trial. This trial was the ﬁrst
randomized, prospective, multicenter, phase III trial to study
the eﬃcacy and safety of ﬁrst-line trastuzumab in HER2-
positive advanced gastroesophageal cancer [60, 68]. The
modest but clinically signiﬁcant overall survival beneﬁt indi-
cated that trastuzumab is a new, eﬀective, and well tolerated
treatment for HER2-positive gastroesophageal cancer. In this
trial, patients with gastroesophageal cancer (n = 3,807)
were centrally tested for HER2 status by IHC and FISH
(patients were eligible if their tumor samples were scoredPathology Research International 5
(a) (b)
(c) (d)
Figure 1: Two gastric tumors analyzed by HER2 immunohistochemistry (IHC, HercepTest) and chromogenic in situ hybridization (CISH).
(a) Case 1 with IHC 2+ score and corresponding (b) CISH ampliﬁcation (see inset). (c) Case 2 with IHC 3+ score and corresponding (d)
CISH ampliﬁcation (see inset).
as 3+ on IHC or if they were FISH positive (HER2:CEP17
ratio ≥2.0), and 22% were HER2 positive. HER2 positivity
washigherinesophagealjunctioncancers(33%)thangastric
cancer (21%), and tumors classiﬁed as intestinal type (32%)
were signiﬁcantly more likely to be HER2-positive than
diﬀuse (only 6%) or mixed (20%) types. Median overall
survival, the primary endpoint, was signiﬁcantly prolonged
in the trastuzumab plus chemotherapy arm when compared
with chemotherapy alone (13.5 months versus 11.1 months;
P = .0048), representing a 26% reduction in the risk
of death in the trastuzumab group (hazard ratio 0.74,
conﬁdence interval 0.60–0.91). The overall response rate was
also signiﬁcantly greater in the trastuzumab arm (47.3%
versus 34.5%; P = .0017). Safety proﬁles were similar in the
two study groups with no unexpected adverse events being
reported with the addition of trastuzumab to chemotherapy.
No clinical data with lapatinib are available so far, but
several phase II studies are ongoing and even a phase III
trial has been initiated. Compared to trastuzumab, lapatinib
is a small molecule tyrosine kinase inhibitor (TKI) that
targets both HER2 and epidermal growth factor receptor
(EGFR/HER1) and can be administered orally. It would be
interesting to see whether the dual action of lapatinib will
provide additional beneﬁt over trastuzumab, especially in
view of the fact that EGFR also seems to be overexpressed
in gastric cancer [91–93].
4. ChangingTreatment of
Esophageal/Gastric Cancer
Despite advances in clinical diagnostics, surgical techniques,
chemotherapy, and radiotherapy regimens, prognosis of
gastric cancer remains poor, and novel treatment options as
well as predictors of treatment response are urgently needed.
Van Cutsem et al. presented preliminary results of the ToGA
study atthe 2009 ASCO Annual Meeting [94]. Although data
fromthistrialshouldbeconsideredencouragingandamajor
step forward in the treatment of advanced gastric cancer,
some important considerations should be made. Firstly,
the absolute beneﬁt in response to trastuzumab addition
to chemotherapy was 12.8%, indicating that—as in breast
cancer—there is also resistance to trastuzumab even among
HER2-positive selected patients. A better understanding of
HER but also of other signalling pathways such as the Wnt
and TGFb pathways is therefore crucial. A combination of
targeted agents, which ideally target diﬀerent “crosstalk”
pathways, would theoretically lead to highly eﬀective thera-
pies [95]. Secondly, although trastuzumab eﬃcacy is likely in
the adjuvant setting, trastuzumab use in early gastric cancer
requires the completion of new adjuvant phase III trials.
Thirdly, although some studies have reported that HER2
ampliﬁcation and overexpression are highly homogeneous
within tumors and between primary and metastatic gastric6 Pathology Research International
cancer [62], others have reported signiﬁcant heterogeneity
in both gene ampliﬁcation and protein overexpression in
individual cancers, even among IHC 3+ cancers [67, 86].
This could impede predicting treatment response and thus
selecting the right patients for treatment.
Future directions of research in HER2-positive gastroe-
sophageal cancer should focus on the evaluation of novel
antibodies (such as pertuzumab, a dimerization inhibitor,
and T-DM1, a drug that combines trastuzumab with a
linked chemotherapy agent called maytansine), irreversible
tyrosine kinase inhibitors (such as neratinib and BIBW 2992,
both dual EGFR-HER2 inhibitors), and inhibitors of HER2-
related downstream signaling (such as mammalian target of
rapamycin (mTOR), heat shock protein 90 (Hsp90), and
PI3K/Akt) and of receptor crosstalk (such as other HER
family members, vascular endothelial growth factor receptor
(VEGFR), and insulin-like growth factor receptor (IGFR)).
In the latter category, some promising targeted agents
have already been investigated in gastroesophageal cancer.
Molecular interactions between HER2 and other members
of its family (HER1 or EGFR, HER3 and HER4) have
led to the development of new targeted therapies such as
the anti-EGFR monoclonal antibody cetuximab, the anti-
EGFRoralsmallmoleculetyrosinekinaseinhibitorserlotinib
and geﬁtinib, and the dual EGFR-HER2 tyrosine kinase
inhibitor lapatinib [96]. Cetuximab has undergone more
extensive evaluation in gastroesophageal cancers than any
other targeted agent in the locally advanced setting as
well as in the ﬁrst-line metastatic setting, the second-line
setting, and beyond. Unfortunately, most of these trial
results have only been published in abstract form, and ﬁnal
publication is eagerly awaited. Cetuximab shows promise in
the treatment of esophageal and gastric cancers in the locally
advanced as well as in the ﬁrst-line metastatic setting. Both
erlotinib and geﬁtinib have very little single-agent activity
in the ﬁrst- and second-line settings in gastroesophageal
cancers. Lapatinib has shown only modest results in the
very few studies evaluating its activity in the metastatic
setting. However, despite these modest results, the phase
III LOGIC trial is currently evaluating the combination of
capecitabine/oxaliplatin with or without lapatinib as ﬁrst-
line therapy in HER2-positive locally advanced, unresectable
or metastatic gastroesophageal cancer.
HER2 has also been shown to communicate with
VEGFR,andstudiesinbreastcancerhaveshownasynergistic
interaction with the combination of trastuzumab and a
VEGFR tyrosine kinase inhibitor [97]. Therapies directed
against VEGF(R) are the focus of ongoing research in
many malignancies including gastroesophageal cancer [98,
99]. Bevacizumab, a monoclonal anti-VEGF antibody, has
been investigated in the locally advanced and metastatic
ﬁrst- and second-line setting with encouraging phase II
results [96]. A conﬁrmatory international phase III trial
of capecitabine/cisplatin with or without bevacizumab in
advanced gastric cancer is currently underway. Sunitinib
and soraﬁnib, both multitarget (among which VEGFR)
tyrosine kinase inhibitors, have been tested in metastatic
gastroesophageal cancers with promising preliminary results
[96].
5. Conclusion andFutureDirections
Based on the encouraging ToGA trial ﬁndings, it is now
expected that routine HER2 testing will be included in the
diagnostic work-up of patients with advanced gastric cancer.
With regard to this testing, overexpression of the HER2
protein seems to possess the best predictive value. However,
HER2 IHC is subject to assay and interobserver variability;
so standardization and internal and external proﬁciency
testing is an absolute prerequisite, especially because the IHC
scoring system in gastric cancer is diﬀerent from that of
breast cancer.
As in breast cancer, trastuzumab research will now most
probably move into the adjuvant setting. The combined
treatment of chemotherapy and trastuzumab may also be
beneﬁcial in decreasing the recurrence of the disease after
resection of the tumor.
Given the high degree of primary and acquired resistance
to trastuzumab therapy and bearing in mind that most
patients with gastroesophageal cancer are HER2-negative,
highly eﬀective therapies can only be accomplished by
a multitargeted approach, considering crosstalk between
pathways and continuing to optimize chemotherapy.
Targeted agents will likely gain an increasingly important
role in the treatment of patients with esophageal and gastric
cancer in the near future, but how big a part they will play is
unclear at this point. Lessons learnt over the past decades in
breast cancer can help us maximize therapy beneﬁt.
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